AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $464,122 | -12.0% | 25,348 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $527,322 | -26.2% | 24,447 | +0.4% | 0.00% | -40.0% |
| Q1 2023 | $714,077 | -19.0% | 24,338 | +2.0% | 0.01% | -16.7% |
| Q4 2022 | $881,368 | +87.1% | 23,853 | +42.5% | 0.01% | +100.0% |
| Q3 2022 | $471,000 | +357.3% | 16,736 | +211.8% | 0.00% | +200.0% |
| Q2 2022 | $103,000 | +68.9% | 5,368 | +12.8% | 0.00% | – |
| Q1 2022 | $61,000 | – | 4,760 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |